Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Series Vol. 6 , 03 August 2023
* Author to whom correspondence should be addressed.
Research Question: Can oridonin inhibit small cell lung cancer growth by blocking the Notch signalling? Purpose: Small cell lung cancer (SCLC) is an aggressive illness with a low 5-year survival rate. Oridonin is a Chinese medicine extracted from the leaves of the Rabdosia rubescens, a traditional Chinese medicinal herb, which has been proven to have many medical effects in opposition to the tumour. Notch signalling is an essential pathway in multicellular organisms and transfers information into living organisms. Methods: This study will use a human small-cell lung cancer cell line (H1688). Migration assay will test the influence of oridonin on cell migration. A Xenograft mouse tumour model is created to determine the effect of oridonin on tumour growth. Annexin V will test cell apoptosis, and a western blot is used to test whether Notch signalling is activated. All the assays are repeated three times, and the statistics are analyzed by calculating the means and doing the student's t-test. Possible results: There are three main possible results:(1) Oridonin can inhibit SCLC growth by blocking the notch signalling. (2) Oridonin can inhibit the tumour growth of SCLC cells but not by blocking notch signalling. (3) Oridonin cannot inhibit tumour growth but can block the notch signalling. Conclusion: The study will show whether oridonin can inhibit the growth of SCLC by blocking the notch signalling. It will provide a new method of treatment for those with SCLCs.
notch signalling, oridonin, SCLC
1. Zhi-Mei, Zhao, Shi-Chao, et al. Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Cancer: A Case Report.[J]. Chung Kuo I Hsueh Ko Hsueh Tsa Chih, 2018.
2. CD Murphy, JM Lee, B Drohan, DM Euhus, DB Kopans, & MA Gadd. (2008). The american cancer society guidelines for breast screening with magnetic resonance imaging : an argument for genetic testing. Cancer.
3. Min, J. , Lee, H. , Lim, H. , Ahn, M. , Park, K. , & Chung, M. , et al. (2011). Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer chemotherapy and pharmacology, 68(5), 1099-109..
4. Landis, S. H. , Murray, T. , Bolden, S. , & Wingo, P. A. . (2010). Cancer statistics, 1998. Ca A Cancer Journal for Clinicians, 48(1), 6-29.
5. Paolo, M., Agnieszka, K. , & Kutas, G. J. . (2001). Cancer chemotherapy: the role of pharmacological agents in the management of hematological malignancies. University of Toronto Medical Journal, 79(1).
6. Visscher, & Maurice, B. . (1976). National library of medicine. Jama the Journal of the American Medical Association, 235(6), 600.
7. Bray, S. J. . (2006). Bray sj. notch signaling: a simple pathway becomes complex. nat rev mol cell biol 7: 678-689. Nature Reviews Molecular Cell Biology, 7(9), 35-42.
8. Wood, M. S. . (2000). U.s. national library of medicine. Health Care on the Internet, 4(1), 80-81.
9. Shawber CJ, Kitajewski J. "Notch function in the vasculature: insights from zebrafish, mouse and man.". Bioessays 26. 2004, pp. 225-234.
10. JFolkman. “Role of angiogenesis in tumor growth and metastasis.”. .Semin Oncol 29. 2002, pp. 15-18.
11. Tolcher AWWA, Mikulski SM, Papadopoulos KP, Kwak EL, et al.Messersmith. (2012): 2348–23. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.”. J Clin Oncol 30. 2012, pp. 2348-2360.
12. Krop IT, Guthrie T, Wen PY, Mason WP, et al.Demuth. “ Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.”. . J Clin Oncol 30. 2012, pp. 2307-2313.
13. Kiec-Wilk BJ, Polus A, Pryjma J, Knapp A, et al.Grzybowska-Galuszka. “ The MAPKdependent regulation of the Jagged/Notch gene expression by VEGF, bFGF or PPAR gamma mediated angiogenesis in HUVEC.”. J Physiol Pharmacol 61. 2010, pp. 217-225.
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).